Xencor and Adlai Nortye add new oncology data as ESMO roundup widens
Xencor reported Phase 1 XmAb819 results in kidney cancer and Adlai Nortye set an AN4035 presentation, joining earlier Nanobiotix, NovaBridge and Eikon ESMO updates.
SEC filing (5)
3 stories
Xencor reported Phase 1 XmAb819 results in kidney cancer and Adlai Nortye set an AN4035 presentation, joining earlier Nanobiotix, NovaBridge and Eikon ESMO updates.
SEC filing (5)
The agreements provide free cetuximab supply for a Phase I trial combining Adlai Nortye's investigational ADC AN4035 with the EGFR antibody in RAS-addicted solid tumors.
SEC filing
The clinical-stage oncology company said Liu, a former equity research analyst, will join as of September 30, 2026 to lead its IR and PR efforts.
SEC filing